StreetAlpha.app
Home › Stocks › ZBIO

Zenas BioPharma, Inc. (ZBIO)

Healthcare
$27.75
▼ −0.64%
LAST CLOSE · NOV 17

Zenas BioPharma develops immune system drugs for autoimmune diseases, led by the antibody candidate obexelimab. It last closed at $27.75 on Nov 17, down 0.64% on the day.

AI Auto Pilots
Is ZBIO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$11.0M
−26.7% vs a year ago
Net income
−$541.8M
−4925.5% margin
EPS (diluted)
−$10.08
−173.7% vs a year ago
Free cash flow
−$242.8M
−2207.6% margin
Valuation
Market cap
$1.9B
67.8M shares
P/E
–
No P/E while losing money
Price to sales
171.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$177.8M
At Sep 30
Debt
$223.2M
At Sep 30
Shareholder equity
$212.3M
Shares outstanding
67.8M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $50.0M$50.0MFY2023FY2024: $5.0M$5.0MFY2024FY2025: $10.0M$10.0MFY2025

From ZBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ZBIO in the past 90 days, not enough for a consensus
Average 12-month target
$48.00
▲ 73.0% upside

Based on 1 analyst who set a price target on ZBIO in the past 90 days. The average target is $48.00, with a high of $48.00 and a low of $48.00, compared with the last close of $27.75.

Low $48.00Avg $48.00High $48.00
Blue marker: last close $27.75
Highest target$48.00
Average target$48.00
Lowest target$48.00
Latest rating changes
CitigroupMaintained
Sep 30Buy$48
Morgan StanleyMaintained
Aug 14Hold$32
WedbushReiterated
Aug 14Buy$45
DateFirmActionRatingPrice target
Sep 30CitigroupMaintainedBuy$48
Aug 14Morgan StanleyMaintainedHold$32
Aug 14WedbushReiteratedBuy$45
Loading…

Technical Analysis

ZBIO · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 1% below its 20 day and 2% below its 50 day average. It is 8% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 49). The nearest support is the Pivot at $27.62, and the nearest resistance the 20 day average at $27.97.

Short trendNeutral
Long trendBullish
MomentumImproving
StretchNormal
VolatilityNormal, 5.9%/day
Key levels
$44.6052 week high+60.7%
$29.55100 day average+6.5%
$29.23Swing high (Oct 1)+5.3%
$28.3850 day average+2.3%
$28.25Pivot R1+1.8%
$27.9720 day average+0.8%
$27.75Last close
$27.62Pivot−0.5%
$27.12Pivot S1−2.3%
$26.68Swing low (Oct 26)−3.9%
$25.44200 day average−8.3%
$13.5052 week low−51.4%
Indicators
RSI (14)48.74Middle of its rangeNeutral
MACD-0.01Above its signal lineBullish
Stochastic49.2Middle of its rangeNeutral
ADX (14)12.7No clear trend
Williams %R-54.3Oversold below −80, overbought above −20Neutral
CCI (20)-55.5Oversold below −100, overbought above 100Neutral
Rate of change−2.2%Change over 10 sessionsBearish
ATR (14)$1.64Typical daily range, 5.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for ZBIO

What happened before

See how ZBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in ZBIO in the last 90 days.

Loading…

See today’s whale options flow across the market →

ZBIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲88 buying vs 48 selling
  • ▲Held by funds +10.1 pts
  • ▲Funds holding +8
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding153145+5.5%
In funds' top 1078−12.5%
Held by funds100.5%90.3%+10.1 pts
New / increased20 / 6827 / 60+1.1%
Reduced / sold out35 / 1339 / 25−25.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ZBIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZBIO is in one of them and how their past ZBIO trades turned out.

ZBIO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ZBIO in an article yet. Here's the latest on the wider market.

About Zenas BioPharma

Zenas BioPharma is a biopharmaceutical company based in Waltham, Massachusetts, that develops drugs targeting the immune system to treat autoimmune diseases. Its lead candidate, obexelimab, is an antibody designed to calm B cells, which play a role in conditions such as IgG4-related disease, relapsing multiple sclerosis and lupus. The company is also developing orelabrutinib, an oral drug for progressive forms of multiple sclerosis, along with several earlier stage candidates. It has no approved products and does not sell drugs today, so its intended customers are patients with autoimmune diseases and the doctors who treat them.

Headquarters
Waltham, MA